{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:42:56Z","timestamp":1765546976685,"version":"3.44.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.virol.2022.09.003","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T08:21:23Z","timestamp":1663662083000},"page":"61-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants"],"prefix":"10.1016","volume":"576","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chulin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desheng","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengfeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2022.09.003_bib1","article-title":"International risk of SARS-CoV-2 Omicron variant importations originating in South Africa","author":"Bai","year":"2021","journal-title":"medRixv"},{"issue":"12","key":"10.1016\/j.virol.2022.09.003_bib2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2022.09.003_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100746","article-title":"mRNA vaccines: a matter of delivery","volume":"32","author":"Cao","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.virol.2022.09.003_bib4","article-title":"BA. 2.12. 1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection","author":"Cao","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.virol.2022.09.003_bib5","first-page":"1","article-title":"Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine","author":"Chalkias","year":"2022","journal-title":"Res. Square"},{"issue":"2","key":"10.1016\/j.virol.2022.09.003_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/21645515.2017.1373227","article-title":"MF59-adjuvanted influenza vaccine (FLUAD\u00ae) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone\u00ae): a randomized, multicenter, Phase III pediatric trial in Mexico","volume":"14","author":"Cruz-Valdez","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"issue":"10321","key":"10.1016\/j.virol.2022.09.003_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.virol.2022.09.003_bib8","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/jmv.27601","article-title":"Emergence of Omicron third lineage BA. 3 and its importance","volume":"94","author":"Desingu","year":"2022","journal-title":"J. Med. Virol."},{"year":"2022","series-title":"Tracking of Variants","key":"10.1016\/j.virol.2022.09.003_bib9"},{"year":"2022","author":"Hachmann","series-title":"Neutralization Escape by the SARS-CoV-2 Omicron Variants BA. 2.12. 1 and BA. 4\/BA. 5","key":"10.1016\/j.virol.2022.09.003_bib10"},{"issue":"2","key":"10.1016\/j.virol.2022.09.003_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/BA20000034","article-title":"Design and production of recombinant subunit vaccines","volume":"32","author":"Hansson","year":"2000","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"13","key":"10.1016\/j.virol.2022.09.003_bib12","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.virol.2022.09.003_bib13","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1080\/21645515.2021.1945901","article-title":"Landscape and progress of global COVID-19 vaccine development","volume":"17","author":"Huang","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2022.09.003_bib14","article-title":"SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies","author":"Ikemura","year":"2021","journal-title":"medRxiv"},{"year":"2021","series-title":"Global attitudes: COVID-19 Vaccines","key":"10.1016\/j.virol.2022.09.003_bib15"},{"issue":"7853","key":"10.1016\/j.virol.2022.09.003_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/d41586-021-00727-3","article-title":"What it will take to vaccinate the world against COVID-19","volume":"592","author":"Irwin","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.virol.2022.09.003_bib17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.vaccine.2022.01.021","article-title":"Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model","volume":"40","author":"Kalnin","year":"2022","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.virol.2022.09.003_bib18","doi-asserted-by":"crossref","first-page":"e1107","DOI":"10.1002\/cti2.1107","article-title":"Assessment of enhanced influenza vaccination finds that FluAd conveys an advantage in mice and older adults","volume":"9","author":"Kavian","year":"2020","journal-title":"Clin Transl immunol."},{"key":"10.1016\/j.virol.2022.09.003_bib19","article-title":"Immunogenicity and safety of Beta adjuvanted recombinant booster vaccine","author":"Launay","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.virol.2022.09.003_bib20","article-title":"Previously infected vaccinees broadly neutralize SARS-CoV-2 variants","author":"Leier","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.virol.2022.09.003_bib21","article-title":"Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study","author":"Li","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.virol.2022.09.003_bib22","article-title":"Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients","author":"Lu","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"6558","key":"10.1016\/j.virol.2022.09.003_bib23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1126\/science.abi4506","article-title":"Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice","volume":"373","author":"Martinez","year":"2021","journal-title":"Science"},{"issue":"7877","key":"10.1016\/j.virol.2022.09.003_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/d41586-021-02383-z","article-title":"The fight to manufacture COVID vaccines in lower-income countries","volume":"597","author":"Maxmen","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.virol.2022.09.003_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jmb.2004.09.079","article-title":"Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable \u03b2-hairpin: atomic details of trimer dissociation and local \u03b2-hairpin stability from residual dipolar couplings","volume":"344","author":"Meier","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"23","key":"10.1016\/j.virol.2022.09.003_bib26","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against covid-19 in Israel","volume":"385","author":"Mevorach","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.virol.2022.09.003_bib27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/jamacardio.2021.2833","article-title":"Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military","volume":"6","author":"Montgomery","year":"2021","journal-title":"JAMA Cardiol."},{"issue":"12","key":"10.1016\/j.virol.2022.09.003_bib28","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"17","key":"10.1016\/j.virol.2022.09.003_bib29","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1016\/j.cell.2021.06.029","article-title":"Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses","volume":"184","author":"Nathan","year":"2021","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.virol.2022.09.003_bib30","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2022.09.003_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","article-title":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","volume":"170","author":"Pollet","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.virol.2022.09.003_bib32","article-title":"Design, immunogenicity and efficacy of a Pan-SARS-CoV-2 synthetic DNA vaccine","author":"Reed","year":"2021","journal-title":"bioRxiv"},{"issue":"23","key":"10.1016\/j.virol.2022.09.003_bib33","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.virol.2022.09.003_bib34","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.virol.2022.09.003_bib35","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.virol.2022.09.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12877-022-03000-y","article-title":"Perceptions of and hesitancy toward COVID-19 vaccination in older Chinese adults in Hong Kong: a qualitative study","volume":"22","author":"Siu","year":"2022","journal-title":"BMC Geriatr."},{"issue":"1","key":"10.1016\/j.virol.2022.09.003_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","article-title":"A mouse model of SARS-CoV-2 infection and pathogenesis","volume":"28","author":"Sun","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.virol.2022.09.003_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3947\/ic.2013.45.2.159","article-title":"Fluad\u00ae-MF59\u00ae-adjuvanted influenza vaccine in older adults","volume":"45","author":"Tsai","year":"2013","journal-title":"Infect. Chemother."},{"key":"10.1016\/j.virol.2022.09.003_bib39","article-title":"Further antibody escape by Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum","author":"Tuekprakhon","year":"2022","journal-title":"bioRivx"},{"issue":"9","key":"10.1016\/j.virol.2022.09.003_bib40","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/vaccines9091033","article-title":"Challenges of storage and stability of mRNA-based COVID-19 vaccines","volume":"9","author":"Uddin","year":"2021","journal-title":"Vaccines"},{"year":"2021","author":"United Nations","series-title":"Unequal Vaccine Distribution Self-Defeating, World Health Organization Chief Tells Economic and Social Council,s Special Ministerial Meeting","key":"10.1016\/j.virol.2022.09.003_bib41"},{"issue":"10269","key":"10.1016\/j.virol.2022.09.003_bib42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.virol.2022.09.003_bib43","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/vaccines10050702","article-title":"A bivalent COVID-19 vaccine based on Alpha and Beta variants elicits potent and broad immune responses in mice against SARS-CoV-2 variants","volume":"10","author":"Wang","year":"2022","journal-title":"Vaccines"},{"issue":"23","key":"10.1016\/j.virol.2022.09.003_bib44","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after Covid-19 vaccination in a large health care organization","volume":"385","author":"Witberg","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10278","key":"10.1016\/j.virol.2022.09.003_bib45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2022.09.003_bib46","article-title":"Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA. 2.11, BA. 2.12. 1, BA. 4 and BA. 5 to therapeutic monoclonal antibodies","author":"Yamasoba","year":"2022","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.virol.2022.09.003_bib47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3947\/ic.2018.50.4.301","article-title":"Phase 4, post-marketing safety surveillance of the MF59-adjuvanted influenza vaccines Fluad\u00ae and Vantaflu\u00ae in South Korean subjects aged\u2265 65 years","volume":"50","author":"Yoo","year":"2018","journal-title":"Infect. Chemother."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682222001507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682222001507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:57:42Z","timestamp":1758589062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682222001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":47,"alternative-id":["S0042682222001507"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2022.09.003","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2022.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}